Tetraphase Pharms Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for TETRAPHASE PHARMS, and what generic alternatives to TETRAPHASE PHARMS drugs are available?
TETRAPHASE PHARMS has one approved drug.
There are three US patents protecting TETRAPHASE PHARMS drugs.
There are seventy patent family members on TETRAPHASE PHARMS drugs in thirty-two countries and seventeen supplementary protection certificates in fifteen countries.
Summary for Tetraphase Pharms
| International Patents: | 70 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Tetraphase Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-002 | Jun 3, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | 8,906,887 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | 8,796,245 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-002 | Jun 3, 2020 | RX | Yes | Yes | 10,961,190 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tetraphase Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Croatia | P20151368 | ⤷ Try a Trial |
| Argentina | 072990 | ⤷ Try a Trial |
| Norway | 2019010 | ⤷ Try a Trial |
| Japan | 2019531321 | ⤷ Try a Trial |
| Croatia | P20130928 | ⤷ Try a Trial |
| Cyprus | 1114689 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tetraphase Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2323972 | SPC/GB19/017 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ERAVACYCLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK PLGB 24626/0005 20180924; UK PLGB 24626/0006 20180924; UK EU/1/18/1312 (NI) 20180924 |
| 2323972 | PA2019009,C2323972 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920 |
| 2323972 | PA2019009 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920 |
| 2323972 | 300971 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ERAVACYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/18/1312 20180924 |
| 2323972 | 12/2019 | Austria | ⤷ Try a Trial | PRODUCT NAME: ERAVACYCLIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1312 (MITTEILUNG) 20180924 |
| 2323972 | 2019C/511 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ERAVACYCLINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
